Drugs / allo-APZ2-EB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03529877 | Feb 2019 → Nov 2021 | recessive dystrophic epidermolysis bullosa | RHEACELL GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allo-APZ2-EB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03529877 ↗ |